Plasma haloperidol and reduced haloperidol concentrations in a geriatric population

Neuropsychobiology

Volumn 33, Issue 1, 1996, Pages 12-16

  Chang, Wen Ho ^a,b   Jann, Michael W ^c   Chiang, Teh Soon ^a   Lin, Hsin Nan ^a,b   Hu, Wei Herng ^a   Chien, Ching Paio ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c MERCER UNIVERSITY   (United States)

Author keywords

Geriatrics; Haloperidol; Plasma levels; Reduced haloperidol

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; REDUCED HALOPERIDOL;

ADULT; AGE; AGED; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030053120     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119242     Document Type: Article

References (24)

1. Solomon K: Haloperidol and the geriatric patient: Practical considerations: in Ayd FJ (ed): Haloperidol Update: 1950-1980, Baltimore, Ayd Medical Communications, 1980, pp 155-173.
2. Coleman JH, Dorevitch AP: Rational use of psychoactive drugs in the geriatric patient, Drug Intell Clin Pharm 1981:15:940-944.
3. Forsman A, Öhman R: Applied pharmacokinetics of haloperidol in man, Curr Ther Res 1977;21:396-410.
4. Froemming JS, Lam YWF, Jann MW, Davis CM: Pharmacokinetics of haloperidol, Clin Pharmacokinet 1989; 17:396-423.
5. Dawling S, Crowe P: Clinical pharmacokinetic considerations in the elderly, Clin Pharmacokinet 1989;17:236-263.
6. Kapetanovic IM, Sweeney DJ, Rapoport SI: Age effects on haloperidol pharmacokinetics in male, Fischer 344 rats, J Pharmacol Exp Ther 1982;221:434-438.
7. Smith DA: New rules for prescribing psychotropics in nursing homes, Geriatrics 1990;45: 44-56.
8. Crismon ML: Psychotropic drugs in the elderly: Principles of use, Am Pharm 1990:NS30: 757-763.
9. Shlllcutt SD, Easterday JL: Geriatric therapeutics: Safe and effective use of antipsychotic agents, Hosp Form 1986:1:462-477.
10. Van Putten T, Marder SR, Mintz J, Poland RE: Haloperidol plasma levels and clinical response: A therapeutic window relationship, ArnJ Psychiatry 1992:149:500-505.
11. Morselli PL, Bianchetti G, Dugas M: Haloperidol plasma level monitoring in neuropsychiatrie patients, Ther Drug Monitor 1982:4:51-58.
12. Dysken MW, Johnson SB, Holden L, Vatassery G, Nygren J, Jelinsky M, Kuskowski M, Schut L, McCarten JR, Knopman D: Haloperidol concentrations in patients with Alzheimer's dementia, Clin Pharmacol Ther 1990:47:162.
13. Viukari M, Salo H, Lamminsivu U, Gordin A: Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients, Acta Psychiatr Scand 1982;65:301-308.
14. Caccia S, Garattini S: Formation of active metabolites of psychotropic drugs, Clin Pharmacokinet 1990:18:434-459.
15. Tyndale RF, Kalow T, Inaba T: Oxidation of reduced haloperidol to haloperidol: involvement of human P450 IID6 (sparteine/debriso-quine monooxygenase), Br J Clin Pharmacol 1991:31:655-660.
16. Chang WH, Lin SK, Jann MW, Urn YWF, Chen TY, Chen CT, Hu WH, Yell EK: Pharmacokinetics and pharmacodynamics of haloperidol and reduced haloperidol in schizophrenic patients, Biol Psychiatry 1989:26:239-249.
17. Llerena A, Alm C, Dahl MJ, Ekqvist B, Bertils-son L: Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype, Ther Drug Monitor 1992:14:92-97.
18. Gilbadi M: Pharmacogenetics: part II, Ann Pharmacotherapy 1992;26:255-261.
19. Huang HF, Jann MW, Tseng YT, Chung MC, Chien CP, Chang WH: Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol treated schizophrenic patients, Psychiatry Res 1995;57:101-108.
20. Llerena A, Dahl MJ, Ekqvist B, Bertilsson L: Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers, Ther Drug Monitor 1992:14:261-264.
21. Nelson JC, Atillasoy E, Mazure C, Jatlow PI: Hydroxydcsipramine in the elderly, J Clin Psy-chopharmacol 1988:8:428-433.
22. Young RC, Alexopoulos GS, Shamoian CA, et al: Plasma 10-hydroxynortriptyline in elderly patients, Clin Pharmacol Ther 1984:35:540-544
23. Chang WH, Jann MW, Lam YWF: Pharmacokinetics of reduced haloperidol, J Clin Pharmacol 1989:29:241.
24. Forsman A, Öhntan R: Studies on serum protein binding of haloperidol, Curr Ther Res 1977:21:245-258.